M1FG
MRTX

Mach-1 Financial Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Mach-1 Financial Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,737
Closed -$555K – 288
2023
Q3 		$555K Buy
+12,737
New +$455K 0.23% 94

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Mach-1 Financial Group's MRTX Position: Q4 2023 in Review

Mach-1 Financial Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 12,737 shares — an estimated $555K sold.

Mach-1 Financial Group first reported a position in MRTX in Q3 2023 and held it in 1 quarter. The position peaked at $555K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Mach-1 Financial Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 12,737 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $555K.
  • Mach-1 Financial Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's Mirati Therapeutics, Inc. Common Stock position peaked at $555K in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Mach-1 Financial Group's 13F filing for Q4 2023, filed 5 Feb 2024.